BBNX Gunggung Aset Perusahaan Beta Bionics Corp

The growth of Beta Bionics Inc (BBNX) relies on scaling the distribution of iLet systems, which requires strict capital management for marketing and insurance payouts. Business success is based on expanding the diabetic customer base and selling profitable components. This price trend for total assets is reflected below as 386.96. Software patents and costly FDA certification, which guarantees user safety, ensure a high barrier to entry.

Beta Bionics Corp - Total Aset Perusahaan BBNX (periode 31.01.2025 - 30.10.2026)

Rincian metrik keuangan lan pasar Beta Bionics Corp (BBNX)

- kuotasi lan prakiraan analis:

Kurs saham betabionics.com|BBNX - Bagan rega target

- data kapitalisasi pasar:

Kapitalisasi pasar iLet Bionic Pancreas|BBNX - Nilai Total Perusahaan

- data nilai buku modal saham:

Nilai Buku Saham Beta Bionics|BBNX - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku betabionics.com|BBNX - Total Aset Perusahaan

- rincian utang lan likuiditas:

Rasio Total Utang marang Ekuitas Beta Bionics Inc|BBNX - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal iLet Bionic Pancreas|BBNX - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku iLet Bionic Pancreas|BBNX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Beta Bionics|Koefisien jangkoan perantara betabionics.com

- rincian asil keuangan lan kelipatan valuasi:

BBNX - Penghasilan resik

Pambiji fundamental:Beta Bionics Inc

This indicator, calculated inversely via return on assets (ROA), reflects the total volume of resources and capital controlled by Beta Bionics Inc. (BBNX) to generate profit. This gross assets chart demonstrates the material base of Beta Bionics Inc., where the increase in the value of equipment and intellectual property confirms the strengthening of its technological advantage in the field of automated diabetes management.

Pesaing utama